Targeting the DNA damage response for cancer therapy

DNA Repair

Volumn 8, Issue 9, 2009, Pages 1153-1165

  Powell, Simon N ^a   Bindra, Ranjit S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Checkpoints; Chromatin; DNA damage response; Double strand break repair; Homologous recombination; Hypoxia; Non homologous end joining; Single strand break repair; Tumor micro environment; Tumor suppressor gene

Indexed keywords

DOUBLE STRANDED DNA;

ARTICLE; CANCER GENETICS; CANCER THERAPY; CELL CYCLE; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

BRCA1 PROTEIN; CHROMATIN; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS; S PHASE;

EID: 68249108128     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2009.04.011     Document Type: Article

References (220)

1. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 9 (2002) 727-730
2. Sarkaria J.N., et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58 19 (1998) 4375-4382
3. Izzard R.A., Jackson S.P., and Smith G.C. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res. 59 11 (1999) 2581-2586
4. Hickson I., et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64 24 (2004) 9152-9159
5. Zhao Y., et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 66 10 (2006) 5354-5362
6. Shinohara E.T., et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res. 65 12 (2005) 4987-4992
7. Ismail I.H., et al. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 23 4 (2004) 873-882
8. O'Connor M.J., Martin N.M., and Smith G.C. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26 56 (2007) 7816-7824
9. Matsuoka S., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316 5828 (2007) 1160-1166
10. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 4 (2007) 275-283
11. Riley T., et al. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9 5 (2008) 402-412
12. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 6381 (1992) 15-16
13. Vogelstein B., and Kinzler K.W. p53 function and dysfunction. Cell 70 4 (1992) 523-526
14. Powell S.N., et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 55 8 (1995) 1643-1648
15. Russell K.J., et al. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res. 55 8 (1995) 1639-1642
16. Fan S., et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55 8 (1995) 1649-1654
17. Tamaoki T. Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Methods Enzymol. 201 (1991) 340-347
18. Senderowicz A.M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther. 2 4 Suppl. 1 (2003) S84-S95
19. Senderowicz A.M. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother. Pharmacol. 52 Suppl. 1 (2003) S61-S73
20. Deplanque G., et al. Caffeine and the G2/M block override: a concept resulting from a misleading cell kinetic delay, independent of functional p53. Int. J. Cancer. 94 3 (2001) 363-369
21. Wang H., et al. Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks. Oncogene 23 3 (2004) 824-834
22. Wang X., et al. Caffeine-induced radiosensitization is independent of nonhomologous end joining of DNA double-strand breaks. Radiat Res. 159 3 (2003) 426-432
23. Weinert T.A., and Hartwell L.H. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241 4863 (1988) 317-322
24. Manke I.A., et al. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302 5645 (2003) 636-639
25. Rodriguez M.C., and Songyang Z. BRCT domains: phosphopeptide binding and signaling modules. Front. Biosci. 13 (2008) 5905-5915
26. Powell S.N., and Kachnic L.A. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med. Chem. 8 4 (2008) 448-460
27. Gowen L.C., et al. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12 2 (1996) 191-194
28. Tirkkonen M., et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57 7 (1997) 1222-1227
29. Xu X., et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3 3 (1999) 389-395
30. Venkitaraman A.R. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J. Cell Sci. 114 Pt 20 (2001) 3591-3598
31. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 2 (2002) 171-182
32. Venkitaraman A.R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. (2008)
33. Morris J.R., Keep N.H., and Solomon E. Identification of residues required for the interaction of BARD1 with BRCA1. J. Biol. Chem. 277 11 (2002) 9382-9386
34. Nishikawa H., et al. Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J. Biol. Chem. 279 6 (2004) 3916-3924
35. Wu-Baer F., et al. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 278 37 (2003) 34743-34746
36. Ouchi T. BRCA1 phosphorylation: biological consequences. Cancer Biol. Ther. 5 5 (2006) 470-475
37. Cantor S.B., et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105 1 (2001) 149-160
38. Yu X., et al. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem. 273 39 (1998) 25388-25392
39. Sobhian B., et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316 5828 (2007) 1198-1202
40. Wang B., et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316 5828 (2007) 1194-1198
41. Paull T.T., et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10 15 (2000) 886-895
42. Kim H., Chen J., and Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316 5828 (2007) 1202-1205
43. Kim H., Huang J., and Chen J. CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat. Struct. Mol. Biol. 14 8 (2007) 710-715
44. Liu Z., Wu J., and Yu X. CCDC98 targets BRCA1 to DNA damage sites. Nat. Struct. Mol. Biol. 14 8 (2007) 716-720
45. Huen M.S., et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131 5 (2007) 901-914
46. Mailand N., et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131 5 (2007) 887-900
47. Kolas N.K., et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 318 5856 (2007) 1637-1640
48. Sartori A.A., et al. Human CtIP promotes DNA end resection. Nature 450 7169 (2007) 509-514
49. Chen L., et al. Cell cycle-dependent complex formation of BRCA1.CtIP. MRN is important for DNA double-strand break repair. J. Biol. Chem. 283 12 (2008) 7713-7720
50. Gupta R., et al. FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein. Blood 110 7 (2007) 2390-2398
51. Litman R., et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8 3 (2005) 255-265
52. Peng M., et al. BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene 25 15 (2006) 2245-2253
53. Greenberg R.A., et al. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev. 20 1 (2006) 34-46
54. Xia B., et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 39 2 (2007) 159-161
55. Xia B., et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 22 6 (2006) 719-729
56. Bae I., et al. BRCA1 regulates gene expression for orderly mitotic progression. Cell Cycle 4 11 (2005) 1641-1666
57. Chabalier C., et al. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5 9 (2006) 1001-1007
58. Wang R.H., Yu H., and Deng C.X. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proc. Natl. Acad. Sci. U.S.A. 101 49 (2004) 17108-17113
59. Xu B., Kim S., and Kastan M.B. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol. Cell Biol. 21 10 (2001) 3445-3450
60. Xu B., et al. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res. 62 16 (2002) 4588-4591
61. Sudakin V., Chan G.K., and Yen T.J. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J. Cell Biol. 154 5 (2001) 925-936
62. Yu H. Regulation of APC-Cdc20 by the spindle checkpoint. Curr. Opin. Cell Biol. 14 6 (2002) 706-714
63. Joukov V., et al. The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 127 3 (2006) 539-552
64. Chabalier-Taste C., et al. BRCA1 is regulated by Chk2 in response to spindle damage. Biochim. Biophys. Acta (2008)
65. Sankaran S., et al. Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. Mol. Cell Biol. 25 19 (2005) 8656-8668
66. Futreal P.A., et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266 5182 (1994) 120-122
67. Merajver S.D., et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat. Genet. 9 4 (1995) 439-443
68. Baldwin R.L., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60 19 (2000) 5329-5333
69. Catteau A., et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 11 (1999) 1957-1965
70. Rio P.G., et al. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int. J. Oncol. 13 4 (1998) 849-853
71. Russell P.A., et al. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int. J. Cancer 87 3 (2000) 317-321
72. Thompson M.E., et al. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9 4 (1995) 444-450
73. Jacinto F.V., and Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22 4 (2007) 247-253
74. Turner N., Tutt A., and Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4 10 (2004) 814-819
75. Bhattacharyya A., et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275 31 (2000) 23899-23903
76. Howlett N.G., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297 5581 (2002) 606-609
77. Kraakman-van der Zwet M., et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell Biol. 22 2 (2002) 669-679
78. Dronkert M.L., and Kanaar R. Repair of DNA interstrand cross-links. Mutat. Res. 486 4 (2001) 217-247
79. Cohn M.A., and D'Andrea A.D. Chromatin recruitment of DNA repair proteins: lessons from the Fanconi anemia and double-strand break repair pathways. Mol. Cell 32 3 (2008) 306-312
80. Hanada K., et al. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. Embo J. 25 20 (2006) 4921-4932
81. De Silva I.U., et al. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell Biol. 20 21 (2000) 7980-7990
82. Rothfuss A., and Grompe M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the Fanconi anemia/BRCA pathway. Mol. Cell Biol. 24 1 (2004) 123-134
83. Chen G.L., et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259 21 (1984) 13560-13566
84. Treszezamsky A.D., et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res. 67 15 (2007) 7078-7081
85. Lafarge S., et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20 45 (2001) 6597-6606
86. Quinn J.E., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63 19 (2003) 6221-6228
87. Tassone P., et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88 8 (2003) 1285-1291
88. Verdine G.L., and Norman D.P. Covalent trapping of protein-DNA complexes. Annu. Rev. Biochem. 72 (2003) 337-366
89. Boudsocq F., et al. Structure-based interpretation of missense mutations in Y-family DNA polymerases and their implications for polymerase function and lesion bypass. DNA Repair (Amst) 1 5 (2002) 343-358
90. Lopes M., Foiani M., and Sogo J.M. Multiple mechanisms control chromosome integrity after replication fork uncoupling and restart at irreparable UV lesions. Mol. Cell 21 1 (2006) 15-27
91. Farmer H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 7035 (2005) 917-921
92. Bryant H.E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 7035 (2005) 913-917
93. Saleh-Gohari N., et al. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol. Cell Biol. 25 16 (2005) 7158-7169
94. Ratnam K., and Low J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13 5 (2007) 1383-1388
95. Lord C.J., and Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8 4 (2008) 363-369
96. Martin S.A., Lord C.J., and Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev. 18 1 (2008) 80-86
97. Tuma R.S. Combining carefully selected drug, patient genetics may lead to total tumor death. J. Natl. Cancer Inst. 99 20 (2007) 1505-1506 1509
98. Albrechtsen N., et al. Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 18 53 (1999) 7706-7717
99. Malkova A., Ivanov E.L., and Haber J.E. Double-strand break repair in the absence of RAD51 in yeast: a possible role for break-induced DNA replication. Proc. Nat. Acad. Sci. U.S.A. 93 14 (1996) 7131-7136
100. Budzowska M., and Kanaar R. Mechanisms of dealing with DNA damage-induced replication problems. Cell Biochem. Biophys. (2008)
101. Barbour L., and Xiao W. Regulation of alternative replication bypass pathways at stalled replication forks and its effects on genome stability: a yeast model. Mutat. Res. 532 1-2 (2003) 137-155
102. Bertrand P., et al. Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogene 14 9 (1997) 1117-1122
103. Dudenhoffer C., et al. Dissociation of the recombination control and the sequence-specific transactivation function of P53. Oncogene 18 42 (1999) 5773-5784
104. Meyn R.E., et al. Radiation-induced apoptosis in normal and pre-neoplastic mammary glands in vivo: significance of gland differentiation and p53 status. Int. J. Cancer 65 4 (1996) 466-472
105. Willers H., et al. Loss of wild-type p53 function is responsible for increased homologous recombination rates in immortalized rodent fibroblasts. Int. J. Radiat. Biol. 76 8 (2000) 1055-1062
106. Willers H., et al. Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene 19 5 (2000) 632-639
107. Saintigny Y., et al. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint. Oncogene 18 24 (1999) 3553-3563
108. Lee H., Larner J.M., and Hamlin J.L. A p53-independent damage-sensing mechanism that functions as a checkpoint at the G1/S transition in Chinese hamster ovary cells. Proc. Nat. Acad. Sci. U.S.A. 94 2 (1997) 526-531
109. Wood R.D. DNA repair in eukaryotes. Annu. Rev. Biochem. 65 (1996) 135-167
110. Dutta A., et al. Inhibition of DNA replication factor RPA by p53. Nature 365 6441 (1993) 79-82 (see comments)
111. Crook T., et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17 13 (1998) 1681-1689
112. Crook T., et al. p53 mutations in BRCA1-associated familial breast cancer. Lancet 350 9078 (1997) 638-639 (letter; see comments)
113. Kanaar R., Hoeijmakers J.H., and van Gent D.C. Molecular mechanisms of DNA double strand break repair. Trends. Cell Biol. 8 12 (1998) 483-489
114. Moynahan M.E., et al. Brca1 controls homology-directed DNA repair. Mol. Cell 4 4 (1999) 511-518
115. Pierce A.J., et al. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13 20 (1999) 2633-2638
116. Sargent R.G., Brenneman M.A., and Wilson J.H. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol. Cell. Biol. 17 1 (1997) 267-277
117. Taghian D.G., and Nickoloff J.A. Chromosomal double-strand breaks induce gene conversion at high frequency in mammalian cells. Mol. Cell. Biol. 17 11 (1997) 6386-6393
118. Zhang J., et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell. Biol. 24 2 (2004) 708-718
119. San Filippo J., Sung P., and Klein H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77 (2008) 229-257
120. Escargueil A.E., et al. What histone code for DNA repair?. Mutat. Res. 658 3 (2008) 259-270
121. Kouzarides T. Chromatin modifications and their function. Cell 128 4 (2007) 693-705
122. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 6765 (2000) 41-45
123. Taverna S.D., et al. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14 11 (2007) 1025-1040
124. Wang G.G., Allis C.D., and Chi P. Chromatin remodeling and cancer. Part I. Covalent histone modifications. Trends Mol. Med. 13 9 (2007) 363-372
125. Redon C., et al. Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 12 2 (2002) 162-169
126. Rogakou E.P., et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273 10 (1998) 5858-5868
127. Downs J.A., et al. Binding of chromatin-modifying activities to phosphorylated histone H2A at DNA damage sites. Mol. Cell 16 6 (2004) 979-990
128. Shroff R., et al. Distribution and dynamics of chromatin modification induced by a defined DNA double-strand break. Curr. Biol. 14 19 (2004) 1703-1711
129. Unal E., et al. DNA damage response pathway uses histone modification to assemble a double-strand break-specific cohesin domain. Mol. Cell. 16 6 (2004) 991-1002
130. Reitsema T., et al. DNA-PK is responsible for enhanced phosphorylation of histone H2AX under hypertonic conditions. DNA Repair (Amst) 4 10 (2005) 1172-1181
131. Mukherjee B., et al. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst) 5 5 (2006) 575-590
132. Stucki M., et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123 7 (2005) 1213-1226
133. Nakamura T.M., et al. Histone H2A phosphorylation controls Crb2 recruitment at DNA breaks, maintains checkpoint arrest, and influences DNA repair in fission yeast. Mol. Cell. Biol. 24 14 (2004) 6215-6230
134. Ward I.M., et al. Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J. Biol. Chem. 278 22 (2003) 19579-19582
135. Toh G.W., et al. Histone H2A phosphorylation and H3 methylation are required for a novel Rad9 DSB repair function following checkpoint activation. DNA Repair (Amst) 5 6 (2006) 693-703
136. Botuyan M.V., et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 127 7 (2006) 1361-1373
137. Ikura T., et al. DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics. Mol. Cell. Biol. 27 20 (2007) 7028-7040
138. Doyon Y., and Cote J. The highly conserved and multifunctional NuA4 HAT complex. Curr. Opin. Genet. Dev. 14 2 (2004) 147-154
139. Jha S., Shibata E., and Dutta A. Human Rvb1/Tip49 is required for the histone acetyltransferase activity of Tip60/NuA4 and for the downregulation of phosphorylation on H2AX after DNA damage. Mol. Cell. Biol. 28 8 (2008) 2690-2700
140. Bird A.W., et al. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature 419 6905 (2002) 411-415
141. Jazayeri A., McAinsh A.D., and Jackson S.P. Saccharomyces cerevisiae Sin3p facilitates DNA double-strand break repair. Proc. Natl. Acad. Sci. U.S.A. 101 6 (2004) 1644-1649
142. Tamburini B.A., and Tyler J.K. Localized histone acetylation and deacetylation triggered by the homologous recombination pathway of double-strand DNA repair. Mol. Cell Biol. 25 12 (2005) 4903-4913
143. Wang R.H., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14 4 (2008) 312-323
144. Qin S., and Parthun M.R. Histone H3 and the histone acetyltransferase Hat1p contribute to DNA double-strand break repair. Mol. Cell. Biol. 22 23 (2002) 8353-8365
145. Qin S., and Parthun M.R. Recruitment of the type B histone acetyltransferase Hat1p to chromatin is linked to DNA double-strand breaks. Mol. Cell. Biol. 26 9 (2006) 3649-3658
146. Choy J.S., and Kron S.J. NuA4 subunit Yng2 function in intra-S-phase DNA damage response. Mol. Cell. Biol. 22 23 (2002) 8215-8225
147. Oishi H., et al. An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification. J. Biol. Chem. 281 1 (2006) 20-26
148. Barlev N.A., et al. Repression of GCN5 histone acetyltransferase activity via bromodomain-mediated binding and phosphorylation by the Ku-DNA-dependent protein kinase complex. Mol. Cell. Biol. 18 3 (1998) 1349-1358
149. Barlev N.A., Workman J.L., and Berger S.L. Analysis of activity and regulation of hGcn5, a human histone acetyltransferase. Methods Enzymol. 304 (1999) 696-715
150. Downs J.A. Histone H3 K56 acetylation, chromatin assembly, and the DNA damage checkpoint. DNA Repair (Amst) (2008)
151. Masumoto H., et al. A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 436 7048 (2005) 294-298
152. Xhemalce B., et al. Regulation of histone H3 lysine 56 acetylation in Schizosaccharomyces pombe. J. Biol. Chem. 282 20 (2007) 15040-15047
153. Driscoll R., Hudson A., and Jackson S.P. Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine 56. Science 315 5812 (2007) 649-652
154. Han J., et al. Rtt109 acetylates histone H3 lysine 56 and functions in DNA replication. Science 315 5812 (2007) 653-655
155. Maas N.L., et al. Cell cycle and checkpoint regulation of histone H3 K56 acetylation by Hst3 and Hst4. Mol. Cell 23 1 (2006) 109-119
156. Celic I., et al. The sirtuins hst3 and Hst4p preserve genome integrity by controlling histone h3 lysine 56 deacetylation. Curr. Biol. 16 13 (2006) 1280-1289
157. Tyler J.K., et al. The RCAF complex mediates chromatin assembly during DNA replication and repair. Nature 402 6761 (1999) 555-560
158. Recht J., et al. Histone chaperone Asf1 is required for histone H3 lysine 56 acetylation, a modification associated with S phase in mitosis and meiosis. Proc. Natl. Acad. Sci. U.S.A. 103 18 (2006) 6988-6993
159. Tsubota T., et al. Histone H3-K56 acetylation is catalyzed by histone chaperone-dependent complexes. Mol. Cell 25 5 (2007) 703-712
160. Chen C.C., et al. Acetylated lysine 56 on histone H3 drives chromatin assembly after repair and signals for the completion of repair. Cell 134 2 (2008) 231-243
161. Chowdhury D., et al. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol. Cell 20 5 (2005) 801-809
162. Chowdhury D., et al. A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. Mol. Cell 31 1 (2008) 33-46
163. Keogh M.C., et al. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature 439 7075 (2006) 497-501
164. Bartek J., and Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr. Opin. Cell Biol. 19 2 (2007) 238-245
165. Carey N., and La Thangue N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. 6 4 (2006) 369-375
166. de Ruijter A.J., et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370 Pt 3 (2003) 737-749
167. Mann B.S., et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 10 (2007) 1247-1252
168. Johnstone R.W., and Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 4 1 (2003) 13-18
169. Chiba T., et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology 66 6 (2004) 481-491
170. Glaser K.B., et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2 2 (2003) 151-163
171. Mariadason J.M., Corner G.A., and Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res. 60 16 (2000) 4561-4572
172. Taddei A., et al. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?. EMBO Rep. 6 6 (2005) 520-524
173. Prasad K.N., et al. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc. Natl. Acad. Sci. U.S.A. 76 2 (1979) 829-832
174. Nackerdien Z., Michie J., and Bohm L. Chromatin decondensed by acetylation shows an elevated radiation response. Radiat. Res. 117 2 (1989) 234-244
175. Camphausen K., et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer 114 3 (2005) 380-386
176. Camphausen K., et al. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res. 10 18 Pt 1 (2004) 6066-6071
177. Cuneo K.C., et al. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs 18 7 (2007) 793-800
178. Geng L., et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 66 23 (2006) 11298-11304
179. Karagiannis T.C., Harikrishnan K.N., and El-Osta A. The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X. Cancer Biol. Ther. 4 7 (2005) 787-793
180. Munshi A., et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther. 5 8 (2006) 1967-1974
181. Zhang Y., et al. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 65 3 (2006) 859-866
182. Chen J.S., and Faller D.V. Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J. Cell Physiol. 202 1 (2005) 87-99
183. Marks P.A., et al. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13 6 (2001) 477-483
184. Banuelos C.A., et al. Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin. Cancer Res. 13 22 Pt 1 (2007) 6816-6826
185. Adimoolam S., et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U.S.A. 104 49 (2007) 19482-19487
186. Camphausen K., and Tofilon P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25 26 (2007) 4051-4056
187. Balasubramanian S., et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22 5 (2008) 1026-1034
188. Chou C.J., Herman D.M., and Gottesfeld J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. (2008)
189. Bristow R.G., and Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8 3 (2008) 180-192
190. Reynolds T.Y., Rockwell S., and Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res. 56 24 (1996) 5754-5757
191. Yuan J., et al. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res. 60 16 (2000) 4372-4376
192. Hammond E.M., Dorie M.J., and Giaccia A.J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem. 278 14 (2003) 12207-12213
193. Hammond E.M., Green S.L., and Giaccia A.J. Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat. Res. 532 1-2 (2003) 205-213
194. Coquelle A., et al. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89 2 (1997) 215-225
195. Young S.D., Marshall R.S., and Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Nat. Acad. Sci. U.S.A. 85 24 (1988) 9533-9537
196. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20 3 (2003) 237-250
197. Coquelle A., et al. Induction of multiple double-strand breaks within an hsr by meganucleaseI-SceI expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements. Oncogene 21 50 (2002) 7671-7679
198. Coquelle A., et al. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell 2 2 (1998) 259-265
199. Li C.Y., et al. Persistent genetic instability in cancer cells induced by non-DNA-damaging stress exposures. Cancer Res. 61 2 (2001) 428-432
200. Bindra R.S., and Glazer P.M. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. Cancer Lett. 252 1 (2007) 93-103
201. Mihaylova V.T., et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell. Biol. 23 9 (2003) 3265-3273
202. Koshiji M., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell. 17 6 (2005) 793-803
203. Rodriguez-Jimenez F.J., et al. Hypoxia causes downregulation of mismatch repair system and genomic instability in stem cells. Stem Cells 26 8 (2008) 2052-2062
204. Bindra R.S., et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 65 24 (2005) 11597-11604
205. Chan N., et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68 2 (2008) 605-614
206. Hammond E.M., et al. Hypoxia links ATR and p53 through replication arrest. Mol. Cell Biol. 22 6 (2002) 1834-1843
207. Hammond E.M., Dorie M.J., and Giaccia A.J. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res. 64 18 (2004) 6556-6562
208. Hammond E.M., and Giaccia A.J. The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst) 3 8-9 (2004) 1117-1122
209. Gibson S.L., Bindra R.S., and Glazer P.M. Hypoxia-induced phosphorylation of Chk2 in an ataxia telangiectasia mutated-dependent manner. Cancer Res. 65 23 (2005) 10734-10741
210. Gibson S.L., Bindra R.S., and Glazer P.M. CHK2-dependent phosphorylation of BRCA1 in hypoxia. Radiat Res. 166 4 (2006) 646-651
211. Bencokova Z., et al. ATM activation and signalling under hypoxic conditions. Mol. Cell Biol. (2008)
212. Bindra R.S., and Glazer P.M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 26 14 (2007) 2048-2057
213. Bindra R.S., et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol. Cell Biol. 24 19 (2004) 8504-8518
214. Meng A.X., et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother. Oncol. 76 2 (2005) 168-176
215. Rockwell S. Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol. Res. 9 6-7 (1997) 383-390
216. Shannon A.M., et al. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 29 4 (2003) 297-307
217. Overgaard J. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25 26 (2007) 4066-4074
218. Bindra R.S., Crosby M.E., and Glazer P.M. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 26 2 (2007) 249-260
219. Zolzer F., and Streffer C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int. J. Radiat. Oncol. Biol. Phys. 54 3 (2002) 910-920
220. Liu S.K., et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother. Oncol. 88 2 (2008) 258-268